Journal: Frontiers in Bioengineering and Biotechnology

Article Title: FBS-Derived Exosomes as a Natural Nano-Scale Carrier for Icariin Promote Osteoblast Proliferation

doi: 10.3389/fbioe.2021.615920

Figure Lengend Snippet: Effects of ICA on osteoblast proliferation. (A) ICA (0.1 μg/mL) promoted osteoblast proliferation; (B) Time dependence of the effect of ICA on osteoblast proliferation activity; and (C) Increased protein expression of BMP-2, RUNX2, and OPN after ICA was applied to MC3T3-E1 cells. * P -value < 0.05 ( n = 4).

Article Snippet: The membranes were incubated overnight at 4°C with specific anti-CD63 (diluted 1: 200; Abcam, United States), anti-CD81 (diluted 1: 500; Abcam, United States), anti-CD40 (diluted 1: 1000; Bioss, China), anti-ALIX (diluted 1: 1000; Abbexa, United Kingdom), anti-RUNX2 (diluted 1: 500, SAB, United States), anti-BMP-2 (diluted 1: 500, Bioworld, United States), anti-OPN (diluted 1: 1000, Proteintech, United States), and anti-GAPDH (diluted 1: 5000, Bioworld, United States).

Techniques: Activity Assay, Expressing

Journal: APL Bioengineering

Article Title: Osteogenically committed hUCMSCs-derived exosomes promote the recovery of critical-sized bone defects with enhanced osteogenic properties

doi: 10.1063/5.0159740

Figure Lengend Snippet: The effects of hUCMSCs-derived PM-Exos and OM-Exos on the migration, proliferation and osteogenic differentiation of hBMSCs. (a) The Transwell chemotaxis assay of hUCMSCs-derived PM-Exos and OM-Exos. (1) control; (2) PM-Exos; and (3) OM-Exos. (b) Relative area of migrated cells compared with the control group. (c) CCK-8 assay to evaluate the proliferation of hBMSCs when being treated with different concentrations of PM-Exos and OM-Exos from day 1 to day 6. (d) Quantitative analysis of ALP activity of hBMSCs on days 4 and 7. (e) qRT-PCR analysis of osteogenesis-related genes expression. (f) and (g) WB assay of BMP-2 expression in hBMSCs and its quantitative analysis on days 7 and 10. (h) ARS staining of hBMSCs on days 9 and 14. * P < 0.05; ** P < 0.01; and *** P < 0.001.

Article Snippet: After reacting with the primary antibody rabbit anti-human BMP-2 (1:1000, Abcam, USA) and the second antibody, the PVDF membrane was photographed and analyzed by Image J analysis software.

Techniques: Derivative Assay, Migration, Chemotaxis Assay, CCK-8 Assay, Activity Assay, Quantitative RT-PCR, Expressing, Staining

Journal: eLife

Article Title: Direct reprogramming of human smooth muscle and vascular endothelial cells reveals defects associated with aging and Hutchinson-Gilford progeria syndrome

doi: 10.7554/eLife.54383

Figure Lengend Snippet: Heat-map representing DE genes between reprogrammed vascular cells from young (N = 3) vs. old (N = 3) donors (iSMCs ( A ), iVECs ( B )). Z score = ± 1.5. DE genes with log 2 FC > 1 and FDR < 0.05. Quantification of BMP2 ( C ) and PALD1 ( D ) expression in human skin biopsies from young vs. old donors (N = 2 donors per condition; N = 10 tissue sections per condition; Student’s t-test with p<0.001 (***) and p<0.05 (*)). Representative images of BMP2 ( E ) and PALD1 ( F ) from skin biopsies obtained from young vs. old donors. Scale bars: 50 µm. Quantification of vascular permeability using young vs. old reprogrammed cells ( G–J ). Schematic showing the generation of an endothelial monolayer covering the interface with a 3D matrix embedding SMCs. Vascular permeability was quantified by measuring the variation of 70 kDa dextran fluorescent intensity across the interface ( G ). Representative images of dextran flow (red) through the endothelial monolayer in presence of young vs. old reprogrammed cells. Scale bar: 100 µm ( H ). Quantification of vascular permeability in presence of young vs. old iVECs (I, at least N = 40 independent measurements per condition in three biological replicates; ANOVA with Holm-Sidak test; comparison with primary VECs (** is p<0.01 and *** is p<0.001); comparison with young iVECs (♦♦♦is p<0.001); comparison with old iVECs (••• is p<0.001)) or young vs. old iSMCs (J, at least N = 40 independent measurements per condition in three biological replicates; ANOVA with Holm-Sidak test; * is p<0.05, ** is p<0.01 and *** is p<0.001). Quantification of vascular permeability in presence of PALD1 KD ( K ) or BMP2 KD ( L ) in primary VECs and SMCs, respectively (at least N = 60 independent measurements per condition in three biological replicates for each KD experiment; Student's t-test; *** is p<0.001).

Article Snippet: Antibody , Anti-human BMP2 (Rabbit polyclonal) , Novus , Cat#nBP1-19751 RRID: AB_2227877 , IF(1:100).

Techniques: Expressing, Permeability, Comparison

Journal: eLife

Article Title: Direct reprogramming of human smooth muscle and vascular endothelial cells reveals defects associated with aging and Hutchinson-Gilford progeria syndrome

doi: 10.7554/eLife.54383

Figure Lengend Snippet: Note that BMP2 KD was validated using qPCR due to technical problems with any of the tested anti-BMP2 antibodies (Western Blot). The use of these antibodies resulted in multiple aspecific bands.

Article Snippet: Antibody , Anti-human BMP2 (Rabbit polyclonal) , Novus , Cat#nBP1-19751 RRID: AB_2227877 , IF(1:100).

Techniques: Western Blot

Journal: eLife

Article Title: Direct reprogramming of human smooth muscle and vascular endothelial cells reveals defects associated with aging and Hutchinson-Gilford progeria syndrome

doi: 10.7554/eLife.54383

Figure Lengend Snippet:

Article Snippet: Antibody , Anti-human BMP2 (Rabbit polyclonal) , Novus , Cat#nBP1-19751 RRID: AB_2227877 , IF(1:100).

Techniques: Transfection, Construct, Retroviral, Expressing, Isolation, Clinical Proteomics, Blocking Assay, Sequencing, Enzyme-linked Immunosorbent Assay, Software